Abatacept survival in rheumatoid arthritis patients at 2 years is 59%; its use as a 2nd line biologic agent and lower baseline HAQ predict better survival in clinical practice: A prospective, observational single center study

Category Primary study
JournalAnnals of the Rheumatic Diseases
Year 2017
This article has no abstract
Epistemonikos ID: c66c024a8faa4a47ed0cbfe8c6a4d605bfde6537
First added on: Mar 24, 2022